- Home
- ONCO vs TOVX Comparison
ONCO vs TOVX Comparison
Compare ONCO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCO
- TOVX
- Stock Information
- Founded
- ONCO 2018
- TOVX 2001
- Country
- ONCO United States
- TOVX United States
- Employees
- ONCO N/A
- TOVX N/A
- Industry
- ONCO Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ONCO Health Care
- TOVX Health Care
- Exchange
- ONCO Nasdaq
- TOVX Nasdaq
- Market Cap
- ONCO 4.7M
- TOVX 3.8M
- IPO Year
- ONCO 2022
- TOVX 2006
- Fundamental
- Price
- ONCO $3.82
- TOVX $0.45
- Analyst Decision
- ONCO
- TOVX Hold
- Analyst Count
- ONCO 0
- TOVX 1
- Target Price
- ONCO N/A
- TOVX N/A
- AVG Volume (30 Days)
- ONCO 266.4K
- TOVX 917.4K
- Earning Date
- ONCO 08-14-2025
- TOVX 11-11-2025
- Dividend Yield
- ONCO N/A
- TOVX N/A
- EPS Growth
- ONCO N/A
- TOVX N/A
- EPS
- ONCO N/A
- TOVX N/A
- Revenue
- ONCO $1,326,959.00
- TOVX N/A
- Revenue This Year
- ONCO N/A
- TOVX N/A
- Revenue Next Year
- ONCO N/A
- TOVX N/A
- P/E Ratio
- ONCO N/A
- TOVX N/A
- Revenue Growth
- ONCO N/A
- TOVX N/A
- 52 Week Low
- ONCO $2.45
- TOVX $0.37
- 52 Week High
- ONCO $552.50
- TOVX $2.64
- Technical
- Relative Strength Index (RSI)
- ONCO 60.58
- TOVX 70.90
- Support Level
- ONCO $3.02
- TOVX $0.39
- Resistance Level
- ONCO $3.24
- TOVX $0.43
- Average True Range (ATR)
- ONCO 0.32
- TOVX 0.03
- MACD
- ONCO 0.04
- TOVX 0.01
- Stochastic Oscillator
- ONCO 80.46
- TOVX 73.14
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.